Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
Authors' conclusion
Patients managed per T2T and those under RC experienced significant improvements in RA disease activity at 12 months of abatacept treatment. T2T was associated with higher odds of CDAI LDA and a shorter time to achieving therapeutic endpoints.
Study context
- Population
- Adults with active to severely active rheumatoid arthritis (RA) initiating subcutaneous abataceptenrolled
- Participants
- 284 adults
- Comparison
- Treat-to-target vs routine care in RA patients initiating SC abatacept
- Treat-to-target (T2T)n = 130
- Routine care (RC)n = 154reference
- Primary endpoint
- Sustained CDAI low disease activity at two consecutive assessments ≈3 months apart
- Follow-up
- 12 months
Methodological detailscluster-randomised
- Cluster-randomised
Primary result
As reported in the abstract
Sustained CDAI LDA
Secondary outcomes
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| CDAI LDA | 1.33 (1.03–1.71) | P = 0.0263 | |
| 0.512Odds ratio (log scale) |
Time to SDAI remission (Kaplan-Meier-estimated)
P = 0.0428
Other secondary outcomes (odds of achieving)
- No significant between-group differences
Time to Simple Disease Activity Index (SDAI) remission (Kaplan-Meier-estimated)
- Trend toward faster Clinical Disease Activity Index (CDAI) low disease activity (LDA)/remission, DAS28-CRP remission and Health Assessment Questionnaire-Disability Index (HAQ-DI) MCID with T2T
Original publication
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept. Arthritis Res Ther. Published 28 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →